L.HerrnstadtC.PrestonG.ThalL.MorrisC
, , -
WO2003045373A1 - Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease - Google Patents Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease Download PDF Info Publication number WO2003045373A1 WO2003045373A1 PCT/IT2002/000745 IT0200745W WO03045373A1 WO 2003045373 A1 WO2003045373 A1 WO 2003045373A1 IT 0200745 W IT0200745 W IT 0200745W WO 03045373 A1 WO03045373 A1 WO 03045373A1 Authority WO WIPO (PCT) Prior art keywords disease carnitine peyronie propionyl medicine Prior art date Legal status (The legal status is an assumption and is not a legal conclusion
Ipamorelin appears to stand out with its selectivity towards hGH, while other GHSs may also interfere with cortisol or prolactin secretion
Finkelstein J, Martin J: Methionine metabolism in mammals: distribution of homocysteine between competing pathways
There are some data that acute COVID-19 infection is accompanied by signs of oxidative stress, including increased expression of ROS-response genes and glycolysis in peripheral blood mononuclear cells [72], increased MDA (TBARS assay), F-isoprostane, 8-hydroxy-2-deoxyguanosine, AOPP and nitrotyrosine levels, and lowered glutathione (GSH), -SH groups, selenium, zinc, TAC and vitamin D [49, 73,74,75,76,77,78,79]
